Polymeric excipients are essential to controlled drug release in LAIs, yet excipient selection remains complex. In this February 10th webinar, USP experts outline an integrated framework for LG polymer naming and characterization, review current USP standards, and share emerging tools designed to support quality, consistency, and regulatory confidence.
IDT Biologika is a global CDMO for vaccines, recombinant proteins, viral vectors, gene & immune therapeutics, monoclonal antibodies, oncolytic viruses and other sterile injectables. End-to-end services in process development, drug substance manufacturing, fill&finish, packaging, quality control and analytics.
With a proven track record of over 100 successful cGMP manufacturing batches and the development of more than 42 biologics and biosimilars, Bora Biologics exemplifies how experience drives success. We offer agile, comprehensive end-to-end CDMO solutions that optimize time and cost efficiencies for biopharma companies around the world. We specialize in a diverse range of biologics, including monoclonal antibodies (mAbs), bi-specifics, fusion proteins, recombinant proteins, and enzymes.
